Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Nanoparticles as theranostic vehicles in prostate cancer.

Morales-Barrera R, Suárez C, Mateo J, González M, Carles J.

Ann Transl Med. 2019 Mar;7(Suppl 1):S29. doi: 10.21037/atm.2019.01.77. No abstract available.

2.

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.

Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J.

Curr Oncol Rep. 2019 Mar 27;21(5):42. doi: 10.1007/s11912-019-0790-6. Review.

PMID:
30919167
3.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW.

J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.

PMID:
30817251
4.

The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.

Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, Prat A, Mellado B.

Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32238. [Epub ahead of print]

PMID:
30807643
5.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F.

BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.

6.

Towards a New Classification for Metastatic Prostate Cancer.

Mateo J, Carles J.

Eur Urol. 2019 Mar;75(3):383-384. doi: 10.1016/j.eururo.2018.10.058. Epub 2018 Nov 19. No abstract available.

PMID:
30466888
7.

Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.

Carles J, Gallardo E, Doménech M, Font A, Bellmunt J, Figols M, Mellado B, Sáez MI, Suárez C, Méndez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, García J, Maciá S, Maldonado X, Foro P.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12.

PMID:
30321689
8.

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.

Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J.

Oncologist. 2019 May;24(5):680-687. doi: 10.1634/theoncologist.2018-0032. Epub 2018 Aug 20.

PMID:
30126859
9.

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.

Carles J, Castellano D, Méndez-Vidal MJ, Mellado B, Saez MI, González Del Alba A, Perez-Gracia JL, Jimenez J, Suárez C, Sepúlveda JM, Manneh R, Porras I, López C, Morales-Barrera R, Arranz JÁ.

Clin Genitourin Cancer. 2018 Dec;16(6):e1133-e1139. doi: 10.1016/j.clgc.2018.07.013. Epub 2018 Jul 21.

PMID:
30104161
10.

An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).

Carles J, Pichler A, Korunkova H, Tomova A, Ghosn M, El Karak F, Makdessi J, Koroleva I, Barnes G, Bury D, Özatilgan A, Hitier S, Katolicka J.

BJU Int. 2019 Mar;123(3):456-464. doi: 10.1111/bju.14509. Epub 2018 Sep 16.

PMID:
30098093
11.

Detection of circulating tumor DNA for advanced bladder cancer: where are we going?

Morales-Barrera R, González M, Suárez C, Carles J.

Transl Androl Urol. 2018 Mar;7(Suppl 1):S101-S103. doi: 10.21037/tau.2018.01.01. No abstract available.

12.

Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.

Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, López-Bigas N, Ramon Y Cajal S, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J.

Clin Cancer Res. 2018 Jun 15;24(12):2812-2819. doi: 10.1158/1078-0432.CCR-17-3800. Epub 2018 Apr 3.

13.

Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M.

Clin Transl Oncol. 2018 Jan;20(1):110-111. doi: 10.1007/s12094-017-1823-y.

PMID:
29305743
14.

Radium-223 international early access program: results from the Spanish subset.

Carles J, Méndez MJ, Pinto Á, Sáez MI, Arranz JA, Maroto P, López-Criado P, Mellado B, Donas JG, Hernando S, León L, Del Alba AG, Laínez N, Esteban E, Reynés G, Pérez-Gracia JL, Germà JR, López-Brea M, Pérez-Valderrama B, Moretones C, Castellano D.

Future Oncol. 2018 Jan;14(1):41-50. doi: 10.2217/fon-2017-0297. Epub 2017 Dec 13.

PMID:
29232987
15.

Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

Slovin S, Clark W, Carles J, Krivoshik A, Park JW, Wang F, George D.

JAMA Oncol. 2018 May 1;4(5):702-706. doi: 10.1001/jamaoncol.2017.3361.

16.

Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.

Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L.

Clin Genitourin Cancer. 2018 Apr;16(2):e491-e496. doi: 10.1016/j.clgc.2017.10.025. Epub 2017 Dec 2.

PMID:
29198640
17.

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).

Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M.

Clin Transl Oncol. 2018 Jan;20(1):57-68. doi: 10.1007/s12094-017-1783-2. Epub 2017 Nov 13. Erratum in: Clin Transl Oncol. 2018 Jan 5;:.

18.

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.

Rodriguez-Vida A, Torregrosa MD, Pinto Á, Climent MÁ, Olmos D, Carles J.

Clin Transl Oncol. 2018 Jun;20(6):679-686. doi: 10.1007/s12094-017-1785-0. Epub 2017 Nov 2. Review.

PMID:
29098556
19.

The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.

Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD.

Eur Urol. 2018 Jul;74(1):17-23. doi: 10.1016/j.eururo.2017.08.035. Epub 2017 Sep 20.

PMID:
28939004
20.

Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone.

Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Chi KN.

Clin Genitourin Cancer. 2017 Jul 25. pii: S1558-7673(17)30211-2. doi: 10.1016/j.clgc.2017.07.014. [Epub ahead of print]

21.

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J.

J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Epub 2017 Aug 15.

PMID:
28809610
22.

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.

Serrano C, George S, Valverde C, Olivares D, García-Valverde A, Suárez C, Morales-Barrera R, Carles J.

Target Oncol. 2017 Jun;12(3):277-288. doi: 10.1007/s11523-017-0490-9. Review.

PMID:
28478525
23.

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.

Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS.

Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3.

PMID:
28344102
24.

Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.

Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Vis DJ, Srinivas S, Morales-Barrera R, Carles J, Al-Rimawi D, Lee S, Kim KH, Izumi K, Lewin J.

Clin Genitourin Cancer. 2017 Aug;15(4):e563-e571. doi: 10.1016/j.clgc.2016.12.014. Epub 2016 Dec 22.

PMID:
28065418
25.

Unveiling changes in the landscape of patient populations in cancer early drug development.

Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J.

Oncotarget. 2017 Feb 21;8(8):14158-14172. doi: 10.18632/oncotarget.13258. Review.

26.

Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.

Regis L, Planas J, Carles J, Maldonado X, Comas I, Ferrer R, Morote J.

Prostate. 2017 Jan;77(1):114-120. doi: 10.1002/pros.23256. Epub 2016 Nov 1.

PMID:
27800640
27.

Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy.

Planas J, Celma A, Placer J, Maldonado X, Trilla E, Salvador C, Lorente D, Regis L, Cuadras M, Carles J, Morote J.

Actas Urol Esp. 2016 Nov;40(9):549-555. doi: 10.1016/j.acuro.2016.02.010. Epub 2016 May 17. English, Spanish.

PMID:
27207596
28.

Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

Morales-Barrera R, Suárez C, de Castro AM, Racca F, Valverde C, Maldonado X, Bastaros JM, Morote J, Carles J.

Cancer Treat Rev. 2016 Nov;50:208-216. doi: 10.1016/j.ctrv.2016.09.018. Epub 2016 Oct 1. Review.

PMID:
27743530
29.

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.

Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. Epub 2016 Aug 27.

PMID:
27575023
30.

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators.

Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.

PMID:
27473888
31.

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.

Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas O.

Cell Rep. 2016 May 10;15(6):1134-43. doi: 10.1016/j.celrep.2016.04.015. Epub 2016 Apr 28.

32.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.

Mesía R, Vázquez S, Grau JJ, García-Sáenz JA, Lozano A, García C, Carles J, Irigoyen A, Mañós M, García-Paredes B, del Barco E, Taberna M, Escobar Y, Cruz JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):289-96. doi: 10.1016/j.ijrobp.2015.10.019. Epub 2015 Oct 22.

PMID:
26675064
33.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Cajal SRY, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.

Nat Commun. 2015 Nov 10;6:8839. doi: 10.1038/ncomms9839.

34.

Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.

Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M.

Clin Genitourin Cancer. 2016 Jun;14(3):255-60. doi: 10.1016/j.clgc.2015.10.006. Epub 2015 Oct 24.

PMID:
26552764
35.

RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.

Serrano C, Romagosa C, Hernández-Losa J, Simonetti S, Valverde C, Moliné T, Somoza R, Pérez M, Vélez R, Vergés R, Domínguez R, Carles J, Ramón Y Cajal S.

Cancer. 2016 Jan 1;122(1):99-107. doi: 10.1002/cncr.29733. Epub 2015 Oct 19.

36.

Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.

Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ.

J Urol. 2015 Nov;194(5):1277-84. doi: 10.1016/j.juro.2015.07.004. Epub 2015 Jul 4.

37.

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J.

Crit Rev Oncol Hematol. 2015 Nov;96(2):308-18. doi: 10.1016/j.critrevonc.2015.05.019. Epub 2015 Jun 8. Review.

PMID:
26100652
38.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators.

Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.

PMID:
25601341
39.

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

Aparicio J, Maroto P, García del Muro X, Sánchez-Muñoz A, Gumà J, Margelí M, Sáenz A, Sagastibelza N, Castellano D, Arranz JA, Hervás D, Bastús R, Fernández-Aramburo A, Sastre J, Terrasa J, López-Brea M, Dorca J, Almenar D, Carles J, Hernández A, Germà JR.

Ann Oncol. 2014 Nov;25(11):2173-8. doi: 10.1093/annonc/mdu437. Epub 2014 Sep 10.

PMID:
25210015
40.

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J.

Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.

41.

Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness.

Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, Carles J, Reventós J, Doll A.

Int J Mol Sci. 2014 Aug 6;15(8):13615-23. doi: 10.3390/ijms150813615.

42.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

43.

Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest.

Morote J, Planas J, Maldonado X, Carles J.

Actas Urol Esp. 2014 Sep;38(7):419-20. doi: 10.1016/j.acuro.2014.02.016. Epub 2014 May 25. English, Spanish. No abstract available.

PMID:
24866537
44.

Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study.

Foro P, Algara M, Lozano J, Rodriguez N, Sanz X, Torres E, Carles J, Reig A, Membrive I, Quera J, Fernandez-Velilla E, Pera O, Lacruz M, Bellosillo B.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1057-63. doi: 10.1016/j.ijrobp.2014.01.002.

PMID:
24661659
45.

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F.

Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6.

46.

Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J.

Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.

PMID:
24570330
47.

Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.

Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A.

PLoS One. 2014 Jan 24;9(1):e86263. doi: 10.1371/journal.pone.0086263. eCollection 2014.

48.

Schwannomas, benign tumors with a senescent phenotype.

Simonetti S, Serrano C, Hernández-Losa J, Bagué S, Orellana R, Valverde C, Lleonart ME, Aizpurua M, Carles J, Ramón y Cajal S, Romagosa C.

Histol Histopathol. 2014 Jun;29(6):721-30. doi: 10.14670/HH-29.721. Epub 2013 Nov 12.

PMID:
24217963
49.

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP.

Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25.

50.

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J.

Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30.

Supplemental Content

Loading ...
Support Center